Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes

被引:32
|
作者
Mu, Pan-wei [1 ]
Chen, Yan-ming [1 ]
Lu, Hong-yun [2 ]
Wen, Xing-qiao [3 ]
Zhang, Yan-hua [1 ]
Xie, Ru-ying [1 ]
Shu, Jiong [1 ]
Wang, Man-man [1 ]
Zeng, Long-yi [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou 510630, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Endocrinol, Zhuhai, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China
关键词
ss-cell function; glycaemic remission; basal insulin; type; 2; diabetes; early intensive control; RESISTANCE; STRATEGIES; INDUCTION; GLUCOSE; FAILURE; OBESE;
D O I
10.1002/dmrr.1292
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Oral anti-diabetes drugs plus basal insulin (OAD+ insulin) therapy in patients with newly diagnosed type 2 diabetes might improve beta-cell function and result in extended glycaemic remission. This randomised trial compared the effect on beta-cell function and diabetes remission rate between oral drug alone or with addition of basal insulin. Methods One hundred and twenty-nine patients, aged 35-50 years, were enrolled between June 2005 and June 2009. For initial correction of hyperglycaemia, patients with fasting plasma glucose >= 9.0 mmol/L and HbA(1c) >= 9.0%, were randomly assigned to therapy with oral drugs+ insulin or oral drugs alone. Treatment was stopped after normoglycaemia was maintained for 3 months. Patients were then followed-up with diet and physical exercise. Blood glucose, HbA(1c) and insulin were measured prior to treatment and at 1-year follow-up. Results More patients achieved target glycaemic control in the oral drugs+ insulin group [98.3% (58 of 59)] in less time [(10.4 +/- 2.5) days] than those in the oral drug group [95.7% (67 of 70) and (12.4 +/- 3.4) days]. At 1-year follow-up, more patients maintained target glycaemia without any drugs in the oral drug+ insulin group than in the oral drug group [37.9% (22 of 58) vs 20.9% (14 of 67)]. Both treatments improved homeostasis model assessment-beta (HOMA-beta) and homeostasis model assessment-insulin resistance (HOMA-IR) significantly. They had similar effects on insulin resistance [lg(HOMA-IR): (0.50 +/- 0.09) vs (0.48 +/- 0.09), p= 0.23]. However, oral drugs+ insulin could recover beta-cell function much more than OAD alone could [lg(HOMA-beta): (2.17 +/- 0.14) vs (2.11 +/- 0.13), p= 0.03]. Conclusion In newly diagnosed type 2 diabetes, therapywith oral drugs+ insulin has had favourable outcomes on recovery and maintenance of beta-cell function and protracted glycaemic remission compared with treatment with oral drugs alone. Copyright c 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:236 / 240
页数:5
相关论文
共 50 条
  • [31] Effects of improved glycaemic control on endothelial function in patients with type 2 diabetes
    Bagg, W
    Whalley, GA
    Gamble, G
    Drury, PL
    Sharpe, N
    Braatvedt, GD
    INTERNAL MEDICINE JOURNAL, 2001, 31 (06) : 322 - 328
  • [32] Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)
    Xu, W.
    Bi, Y.
    Sun, Z.
    Li, J.
    Guo, L.
    Yang, T.
    Wu, G.
    Shi, L.
    Feng, Z.
    Qiu, L.
    Li, Q.
    Guo, X.
    Luo, Z.
    Lu, J.
    Shan, Z.
    Yang, W.
    Ji, Q.
    Yan, L.
    Li, H.
    Yu, X.
    Li, S.
    Zhou, Z.
    Lv, X.
    Liang, Z.
    Lin, S.
    Zeng, L.
    Yan, J.
    Ji, L.
    Weng, J.
    JOURNAL OF INTERNAL MEDICINE, 2015, 277 (01) : 137 - 150
  • [33] Beneficial Effects of Insulin on Glycemic Control and β-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy
    Chen, Harn-Shen
    Wu, Tzu-En
    Jap, Tjin-Shing
    Hsiao, Li-Chuan
    Lee, Shen-Hung
    Lin, Hong-Da
    DIABETES CARE, 2008, 31 (10) : 1927 - 1932
  • [34] Socioeconomic inequalities in glycaemic control in people with newly diagnosed type 1 and type 2 diabetes
    Jacobs, E.
    Strassburger, K.
    Icks, A.
    Kuss, O.
    Burkhart, V.
    Szendroedi, J.
    Muessig, K.
    Rathmann, W.
    Roden, M.
    DIABETOLOGIA, 2018, 61 : S420 - S420
  • [35] Short-Term Effects of Basal-Plus Insulin Therapy on Early Remission of Newly Diagnosed Type 2 Diabetes
    Woks, Emma
    Etoga, Martine Claude Etoa Ndzie
    Namba, Raicha
    Katte, Jean Claude Njabou
    Mbanya, Jean Claude
    Sobngwi, Eugene
    DIABETES, 2018, 67
  • [36] Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes
    Vidal, J
    Fernández-Balsells, M
    Sesmilo, G
    Aguilera, E
    Casamitjana, R
    Gomis, R
    Conget, I
    DIABETES CARE, 2000, 23 (03) : 360 - 364
  • [37] Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes
    Wei Zhang
    Hongdong Wang
    Fangcen Liu
    Xiao Ye
    Wenjuan Tang
    Pengzi Zhang
    Tianwei Gu
    Dalong Zhu
    Yan Bi
    Diabetes Therapy, 2022, 13 : 679 - 690
  • [38] Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes
    Wang, Hongdong
    Bi, Yan
    Liu, Fangcen
    DIABETES, 2018, 67
  • [39] Effects of Early Intensive Insulin Therapy on Endothelial Progenitor Cells in Patients with Newly Diagnosed Type 2 Diabetes
    Zhang, Wei
    Wang, Hongdong
    Liu, Fangcen
    Ye, Xiao
    Tang, Wenjuan
    Zhang, Pengzi
    Gu, Tianwei
    Zhu, Dalong
    Bi, Yan
    DIABETES THERAPY, 2022, 13 (04) : 679 - 690
  • [40] Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
    Dorkhan, M.
    Magnusson, M.
    Frid, A.
    Grubb, A.
    Groop, L.
    Jovinge, S.
    JOURNAL OF INTERNAL MEDICINE, 2006, 260 (02) : 125 - 133